11/21
07:40 am
alpmy
Optical Imaging Agent Market Expected to Expand at 8.1% CAGR, Reaching US$ 3,533.2 Million by 2034 | Fact.MR Report [Yahoo! Finance]
Low
Report
Optical Imaging Agent Market Expected to Expand at 8.1% CAGR, Reaching US$ 3,533.2 Million by 2034 | Fact.MR Report [Yahoo! Finance]
11/20
01:19 pm
alpmy
Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management [Yahoo! Finance]
Low
Report
Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management [Yahoo! Finance]
11/20
01:00 pm
alpmy
Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management
Low
Report
Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management
11/18
08:22 am
alpmy
KaliVir Immunotherapeutics Strengthens Innovation Portfolio with Issuance of Three New U.S. Patents Covering Its VET™ Product Candidates [Yahoo! Finance]
Low
Report
KaliVir Immunotherapeutics Strengthens Innovation Portfolio with Issuance of Three New U.S. Patents Covering Its VET™ Product Candidates [Yahoo! Finance]
11/12
11:02 am
alpmy
Should Value Investors Buy Astellas Pharma (ALPMY) Stock? [Yahoo! Finance]
Low
Report
Should Value Investors Buy Astellas Pharma (ALPMY) Stock? [Yahoo! Finance]
11/5
05:06 pm
alpmy
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday [Yahoo! Finance]
Low
Report
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday [Yahoo! Finance]
10/30
04:52 am
alpmy
Astellas Pharma reports H1 results [Seeking Alpha]
Medium
Report
Astellas Pharma reports H1 results [Seeking Alpha]
10/18
02:15 pm
alpmy
Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer [Yahoo! Finance]
Low
Report
Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer [Yahoo! Finance]
10/18
02:13 pm
alpmy
Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
Low
Report
Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
10/10
01:00 pm
alpmy
FDA Grants iota Biosciences IDE Approval for First-In-Human Early Feasibility Study with Implantable Bladder Device
Low
Report
FDA Grants iota Biosciences IDE Approval for First-In-Human Early Feasibility Study with Implantable Bladder Device
10/10
03:05 am
alpmy
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause [Yahoo! Finance]
Low
Report
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause [Yahoo! Finance]
10/10
03:00 am
alpmy
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause
Low
Report
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause
10/9
10:44 am
alpmy
KaliVir doses first subject in Phase I/Ib solid tumour treatment trial [Yahoo! Finance]
Low
Report
KaliVir doses first subject in Phase I/Ib solid tumour treatment trial [Yahoo! Finance]
10/8
09:45 am
alpmy
Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications [Yahoo! Finance]
Low
Report
Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications [Yahoo! Finance]
10/8
09:27 am
alpmy
Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications
Low
Report
Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications
10/2
11:42 am
alpmy
Are Investors Undervaluing Astellas Pharma (ALPMY) Right Now? [Yahoo! Finance]
Low
Report
Are Investors Undervaluing Astellas Pharma (ALPMY) Right Now? [Yahoo! Finance]
9/24
02:05 am
alpmy
Japan's Ministry of Health, Labour and Welfare Approves PADCEV™ (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma
Low
Report
Japan's Ministry of Health, Labour and Welfare Approves PADCEV™ (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma
9/20
09:42 am
alpmy
Astellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer [Yahoo! Finance]
Low
Report
Astellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer [Yahoo! Finance]
9/20
09:17 am
alpmy
Astellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
Low
Report
Astellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
9/19
05:36 am
alpmy
FDA lists Astellas' digital health solution for heart failure management [Yahoo! Finance]
Low
Report
FDA lists Astellas' digital health solution for heart failure management [Yahoo! Finance]
9/18
07:30 pm
alpmy
Astellas Announces FDA Listing of DIGITIVA™ for the Management of Heart Failure
Low
Report
Astellas Announces FDA Listing of DIGITIVA™ for the Management of Heart Failure
9/11
02:00 am
alpmy
Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024
Low
Report
Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024
9/5
10:00 am
alpmy
Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies
Low
Report
Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies
9/4
08:00 am
alpmy
Astellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society
Low
Report
Astellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society
8/27
07:37 pm
alpmy
European Commission Approves Astellas' PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer [Yahoo! Finance]
Low
Report
European Commission Approves Astellas' PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer [Yahoo! Finance]